Article
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
British journal of cancer - 19 Mar 2013
Miles D W, de Haas S L, Dirix L Y, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar P R, Scherer S J
Abstract excerpt
BACKGROUND: Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC). However, identification of patients benefitting most from bevacizumab remains elusive. The AVADO trial included an extensive optional exploratory biomarker programme. METHODS: Patients with HER2-negative mBC were randomised to receive docetaxel with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.